Team:Newcastle/HP/Gold Integrated

spacefill

Human Practices (Gold & Integrated)

Aims and Rationale

Sensynova was a project founded in Human Practices. Each branch of our project is rooted in a barrier to biosensor implementation identified by in-depth conversations with stakeholders. We identified not only technical issues, but also societal issues, as these are equally important in ensuring successful implementation of biosensor projects.

The aims of our human practices were to:
1 - Determine how current biosensor developers design, produce and implement biosensor projects
2 - Use these talks to determine the common barriers to biosensor development and implementation
3 - Create novel solutions to identified problems, producing frameworks and guidelines to aid future researchers

To achieve these aims, we emailed, skyped and attended conferences to speak to stakeholders in biosensor development, from the early research stage to the end-user.

Introduction

Synthetic Biology biosensors have a number of advantages over traditional methods. They are cost-effective (After the research stages, production of the biosensor relies only on the maintenance of a population of cells expressing an engineered system), can produce a variety of sophisticated behaviours, such as signal amplification and logic gates, and often have no reliance on additional equipment and therefore are ideal for onsite diagnosis.

Each year a plethora of useful biosensors are developed, both by iGEM researchers and in the broader synthetic biology community. We now have access to biosensors for applications ranging from water contamination to fruit ripeness. In fact, we had originally decided on the development of a biosensor for herbicides as our iGEM project. However, our research for this project unearthed an interesting fact: despite the large number of synthetic biology biosensors that have been developed over the years, there is a distinct lack of synthetic biology based biosensors in everyday use. Despite their advantages over methods like immunoassays and mass spectroscopy (which are expensive and often rely on additional equipment), these traditional methods are much more widely used by researchers. Also, the day-to-day usage by non-scientists, who are often the target end-user for a biosensor, has not materialised. In fact, not one synthetic biology based biosensor has been approved for use outside of a laboratory setting by the EU.

This led to the question which shaped not only our human practices work, but our project as a whole: What are the barriers facing synthetic biology biosensors, and what can we do to help?

The Issues

Issue #1: Parts Reusability

“Each generation of scientists keeps reinventing the wheel” - Dr Martin Peacock

The Issue

When talking to experts about biosensor development, a common theme that came up was the rediscovery and work done on commonly used biosensor parts which lengthened the development process as well as limited resources for novel findings. We talked to Dr Martin Peacock, a hardware biosensor developer, about this and he mentioned how this limits his hardware development and that having common part reusability would combat this problem.

Our Solution

Our solution to this problem was the creation of the modularity aspect of the Sensynova biosensor development platform. As part of the platform, developers can switch in and out different components of each device (adaptor, detector, processor and reporter) isolated in different cells, and co-culture these together so there is an easy switch in-switch out system. Variants of the devices could then be distributed in agar slabs, as a biosensor development kit.

Issue #2: Range of Analytes and Outputs

“Main bulk of the work in developing a biosensor is the deduction of the mechanistic process of substrate-circuit interaction” - Dr Oliver Purcell

The Issue

The majority of work done in the research and development around biosensor development is the deduction of native interactions between a target molecule and binding site. There are also many substrates which don’t have a known binding site. Upon discussion with biosensor developer Dr Oliver Purcell, he told us that this took up a large chunk of time during development.

Our Solution

To combat this issue, we have created a synthetic promoter library which a large number of substrates that don’t have a known binding sequence can be screened against. The screening would find a promoter that was induced by that substrate. This takes the focus from the biological knowledge and onto the engineering of the biosensor. Also we have developed an adaptor module, which can link a substrate like the ones above into our system by breaking into down into a compound that has a known binding sequence.

Issue #3: Legislation

“The main problem with using biosensors outside the lab is legislation” - Dr Chris French

The Issue

The use of synthetic biology based biosensors is limited in the field due to restrictions around the use of genetically modified organisms outside controlled areas. Speaking to Dr Chris French on this matter, he told us about his experience with this issue when trying to get clearance for the use of the arsenic biosensor in the field. It became clear that this was the only hurdle in this project and that it was the reason the project has come to a stand still.

Our Solution

During our discussions with Dr French, he pointed us in the direction of the Workshop on Biosensors that took place in. This report said that “a possible solution to getting around legislative restrictions is the use of cell systems”. After reading this and along with our discussions with experts, we went forward and created a mixed cell free system, informed by a design of experiments model to be able to implement our system in a cell free manner, in the future

Issue #4: Extensive Optimisation

“Optimisation of a system is another time consuming step in development” - Dr Chris French

The Issue

Tighty coupled whole cell biosensors require extensive genetic engineering to optimise the system e.g the breaking apart the components and reassembly including changes to optimise the system.

Our Solution

Our development platform allows the interchangeability of parts across the full biosensor and the modularity aids easy optimisation as changes can be made to one part if necessary or the part can be swapped out for another, be relating it with the new device in a different cell, then reculturing

Issue #5: Uptake of Technologies

“Only the top 5% of an industry will pick up new technologies, and we rely on them feeding it down" - Dr David George

The Issue

When researching a concept for the project, we attend the N8 Crop and Agriculture Innovation Conference where we heard a talk of Dr David George, who was speaking about the uptake of new technologies among agriculture industries. He said the only a small percentage of the top of an industry will pick up a new technology then it is relied to filter down the industry. Professor Rick Mumford also spoke on the long process from lab to field and that improvements of the innovation pipeline can be made at every level, including deployment.

Our Solution

We have looked at this issue from a communication angle and extensively analysed the current profile of SynBio in the media as well as producing guidelines for future science communication. We did this to help future teams and scientists on how to best communicate their work and help deployment of technologies to the public.


Conclusion

The possibilities of synthetic biology biosensors are wide reaching from diagnostic applications to bioremediation. Their advantages include low equipment requirements and portability in the field. But there are still many hang ups in their development and deployment. As a team, from all our skype calls, emails, conferences and own research we have identified these 5 main issue have influenced how we have addressed our project. We recognise there are other issues in biosensor development which were not able to be considered in the scope of this project; sample backgrounds and speed are two problems which, in the future, can be tackled. On the whole, we went with problems that we had established were major ones and offered our solutions to each.

Our project demonstrates the importance of early stage human practice discussions. Additionally, a willingness to facilitate honest discussions about not only the advantages of a synthetic biology approach but the current limits of the technology is essential in .

We hope that in addressing the barriers outlined here, we have facilitated the progression of synthetic biology biosensors, bringing us closer to a future in which the broad range of biosensors developed are utilised and impact our lives on a day-to-day basis.

Advice to future teams

We advise future iGEM teams to begin early with human practice discussions. We approached stakeholders in our project within a month of settling on a project idea: well before the summer had started and wetlab work began. This means that projects still have the plasticity to adjust following discussions, even if that means a complete change of project, as happened for us.

We would also advise attending conferences outside of the field of synthetic biology.

Finally, do not be afraid to ask the difficult questions. As new inductees to the field of synthetic biology, iGEM team members are perhaps some of the best suited for identification of bigger issue problems in the synthetic biology. For us, this was the inability to be able to point to an example of a synthetic biology produced biosensor in use in everyday life. Therefore, we encourage other teams to follow our example: iGEM teams have been hugely successful in identifying problems in many areas - we propose that turning this insight on our own field is equally important.